Saihong Ignatius Ou

42PUBLICATIONS
201CO-AUTHORS
Molecular targetsSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Oct 08, 2026
Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer.

|Oct 04, 2026
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Jan 01, 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.

Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter

|Nov 06, 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.

Yanyan Hu, Sai-Hong Ignatius Ou

Pageof 7

Frequent Collaborators

15 joint publications

Misako Nagasaka

7 joint publications

Zhaohui Liao Arter

6 joint publications

Alexandria T M Lee

4 joint publications

Alexander Drilon